HR−/HER2+ and TN breast cancers tend to respond rapidly to treatment, with pCR rates up to 70% for HR−/HER2+ and in the range of 22–60% for TN in I-SPY 2 and other trials [19]. This evidence concerns the gene ERBB2 and breast carcinoma.